EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients

Cancer Cytopathology

Volumn 121, Issue 10, 2013, Pages 552-560

  Malapelle, Umberto ^a   Bellevicine, Claudio ^a   De Luca, Caterina ^a   Salatiello, Maria ^a   De Stefano, Alfonso ^a   Rocco, Danilo ^b   De Rosa, Nicla ^b   Vitiello, Fabiana ^b   Russo, Stefania ^a   Pepe, Francesco ^a   Iaccarino, Antonino ^a   Micheli, Pietro ^b   Illiano, Alfonso ^b   Carlomagno, Chiara ^a   Piantedosi, Franco Vito ^b   Troncone, Giancarlo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AORN Vincenzo Monaldi   (Italy)

Author keywords

Adenocarcinoma; Cytopathology; Epidermal growth factor receptor; Gefitinib; Lung cancer; Molecular testing

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CENTRALIZATION; CLINICAL PRACTICE; CONTROLLED STUDY; CYTOLOGY; DILUTION; DRUG RESPONSE; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; LIMIT OF DETECTION; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOLECULAR CLONING; MUTATIONAL ANALYSIS; PLEURA EFFUSION; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RELIABILITY; SARCOMATOID CARCINOMA; TREATMENT OUTCOME; VERY ELDERLY; ADENOCARCINOMA; CYTODIAGNOSIS; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; CYTOPATHOLOGY; LUNG CANCER; MOLECULAR TESTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYTODIAGNOSIS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

ADENOCARCINOMA; CYTOPATHOLOGY; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LUNG CANCER; MOLECULAR TESTING;

EID: 84891546802     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21322     Document Type: Article

References (26)

1. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol. 2011;119: 80-91.
2. Dumur CI, Idowu MO, Powers CN. Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine. Cancer Cytopathol. 2013;121: 61-71.
3. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: review of the evidence. Lung Cancer. 2011;71: 249-257.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361: 947-957.
5. Malapelle U, Bellevicine C, Zeppa P, Palombini L, Troncone G. Cytology-based gene mutation tests to predict response to antiepidermal growth factor receptor therapy: a review. Diagn Cytopathol. 2011;39: 703-710.
6. Allegrini S, Antona J, Mezzapelle R, et al. Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma. Am J Clin Pathol. 2012;138: 377-381.
7. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119: 111-117.
8. Pang B, Matthias D, Ong CW, et al. The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases. Cytopathology. 2012;23: 229-236.
9. Malapelle U, de Rosa N, Rocco D, et al. EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol. 2012;65: 87-91.
10. Savic S, Tapia C, Grilli B, et al. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of nonsmall-cell lung cancers. Br J Cancer. 2008;98: 154-160.
11. Molina-Vila MA, Bertran-Alamillo J, Reguart N, et al. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells. J Thorac Oncol. 2008;3: 1224-1235.
12. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Mod Pathol. 2012;25: 548-555.
13. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol. 2011;29: 2972-2977.
14. Han HS, Lim SN, An JY, et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using 2 methods of differential sensitivity. J Thorac Oncol. 2012;7: 355-364.
15. Oshita F, Matsukuma S, Yoshihara M, et al. Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer. Br J Cancer. 2006;95: 1070-1075.
16. Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist. 2011;16: 877-885.
17. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6: 244-285.
18. Malapelle U, Carlomagno C, Salatiello M, et al. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer. 2012;107: 626-631.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
20. Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH. High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas [published online ahead of print December 5, 2012]. Cancer Cytopathol. 2012.
21. Clark DP. Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol. 2009;117: 289-297.
22. Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011;6: 1849-1856.
23. da Cunha Santos G, Lai SW, Saieg MA, et al. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a 9 year period and analysis of factors underlying failure to subtype. Lung Cancer. 2012;77: 501-506.
24. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res. 2006;12: 43-48.
25. Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer. 2006;119: 2353-2358.
26. Kimura H, Fujiwara Y, Sone T, et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci. 2006;97: 642-648.